article · Mediterranean Journal of Rheumatology
Objective: Our study aims to evaluate the effectiveness of anti-tumour-necrosis-factor Infliximab (IFX) in treating patients with severe and/or refractory vascular manifestations of Behçet's disease (BD) through a systematic review and meta-analysis. Methods: statistics. Random effects models were used for all statistical analyses which were conducted on R software (version 4.4.2), PROSPERO registry number CRD42025640970 Results: Of the 2127 results initially identified, 11 studies with a total of 284 patients were included in the final analysis. Infliximab induced complete vascular response in 78.17% of patients (95% CI 63.11-90.61). The remission rates in the subgroups of patients with pulmonary artery aneurysm and the venous thrombosis events were respectively 99.13% (95% CI 86.21-100) and 86.48 % (95% CI 71.81-97.15). Conclusion: Our systematic review and meta-analysis support the use of infliximab in patients with severe and/or refractory vascular Behçet's disease, particularly in cases involving pulmonary artery aneurysms.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.31138/mjr.080325.tav
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
